NCT05038592View on ClinicalTrials.gov

Phase I/II Study of Tagraxofusp in Combination With Decitabine for Patients With Myelomonocytic/Myeloproliferative Neoplasm and High Risk Myelodysplastic Syndromes

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

64

Participants

Timeline

Start Date

March 4, 2022

Primary Completion Date

January 29, 2026

Study Completion Date

January 29, 2026

Conditions
Chronic Myelomonocytic LeukemiaChronic Myelomonocytic Leukemia-1Chronic Myelomonocytic Leukemia-2Myelodysplastic/Myeloproliferative Neoplasm
Interventions
DRUG

Decitabine

Given IV

BIOLOGICAL

Tagraxofusp-erzs

Given IV

Trial Locations (1)

77030

RECRUITING

M D Anderson Cancer Center, Houston

All Listed Sponsors
lead

M.D. Anderson Cancer Center

OTHER

NCT05038592 - Phase I/II Study of Tagraxofusp in Combination With Decitabine for Patients With Myelomonocytic/Myeloproliferative Neoplasm and High Risk Myelodysplastic Syndromes | Biotech Hunter | Biotech Hunter